Skip to main content
Fig. 3 | Experimental Hematology & Oncology

Fig. 3

From: Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases

Fig. 3

Comparison of PFS and OS between ICI based monotherapy and combination therapy in patients with brain metastases. (A), Comparison of PFS between ICI based monotherapy and combination therapy in patients with brain metastases; (B), Comparison of OS between ICI based monotherapy and combination therapy in patients with brain metastases; (C), Comparison of PFS among ICI based monotherapy, ICI plus chemotherapy and ICI plus anti-angiogenic therapy (including ICI plus chemotherapy and anti-angiogenic therapy) in patients with brain metastases; (D), Comparison of OS among ICI based monotherapy, ICI plus chemotherapy and ICI plus anti-angiogenic therapy (including ICI plus chemotherapy and anti-angiogenic therapy) in patients with brain metastasis

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us